Olumiant (baricitinib) is a Disease Modifying Anti-Rheumatic Drug (DMARD) currently used to treat rheumatoid arthritis with and without methotrexate. Its effectiveness is currently being studied for other types of arthritis.
Olumiant works by suppressing the immune system. It belongs to a class of medications known as Janus Kinase (JAK) inhibitors.
Olumiant is one of the few therapies for arthritis that is available as an oral tablet. The standard dose is 2-4 mg taken once every day.
Olumiant does not work right away. It can take about 2 to 8 weeks before patients start feeling better, and it can take 3 to 6 months to feel the maximum effect of this medication. If the dose is changed, it can take 2 to 8 weeks to feel the effects.
The manufacturer of Olumiant offers a support program to Canadian patients that are prescribed the medication:Patient support program enrolment forms
Important Tests and Risks
Drug Identification Number (DIN)